NPI 1447874268: Open Payments
NPI 1447874268. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,527 in 87 payments from 13 companies in 2025. Trend: 2023 $346 · 2024 $1,129 · 2025 $2,527
Food & beverage: $2,425Education: $102
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 11 | $377 |
| Galderma Laboratories, L.P. | 9 | $312 |
| Janssen Biotech, Inc. | 4 | $281 |
| ABBVIE INC. | 15 | $281 |
| Arcutis Biotherapeutics, Inc. | 9 | $246 |
| LEO Pharma Inc. | 11 | $239 |
| Novartis Pharmaceuticals Corporation | 7 | $238 |
| Incyte Corporation | 6 | $185 |
| Regeneron Healthcare Solutions, Inc. | 8 | $160 |
| GENZYME CORPORATION | 3 | $122 |
Products named: Bimzelx, NEMLUVIO, DUPIXENT, TREMFYA, Zoryve, ADBRY, SKYRIZI, OPZELURA.
